Portfolio
Our Intellectual Property portfolio is based on small molecules as potential drug candidates directed to a wide range of cancer indications.
ARD-017 is our lead compound, which by blocking TMEM176B/A, unbridles inflammation breaks that control tumor growth thereby improving survival in preclinical models of solid and liquid tumors in the absence of any overt signs of systemic toxicity and no immune mediated adverse effects.
Scientific Platform
“Targeting TMEM176B/A in the Cancer Immunity Cycle”
TMEM176B/A blockade triggers systemic anti-tumoral immunity involving the intestinal compartment, secondary lymphoid organs and the tumor microenvironment. Inflammasome activation, CD4 and exhausted CD8+ T cells are involved in these mechanisms.